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Key Points  32 
Npm1c and Nras-G12D co-mutation in mice leads to AML with a longer latency and a more 33 
mature phenotype than the Npm1c/Flt3-ITD combination 34 
Mutant Flt3 or Nras allele amplification is the dominant mode of progression in Npm1c/Flt3-35 
ITD and Npm1c/Nras-G12D murine AML  36 
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Abstract 37 
NPM1 mutations define the commonest subgroup of acute myeloid leukemia (AML) and 38 
frequently co-occur with FLT3 internal tandem duplications (ITD) or, less commonly, NRAS 39 
or KRAS mutations. Co-occurrence of mutant NPM1 with FLT3-ITD carries a significantly 40 
worse prognosis than NPM1-RAS combinations. To understand the molecular basis of these 41 
observations we compare the effects of the two combinations on hematopoiesis and 42 
leukemogenesis in knock-in mice. Early effects of these mutations on hematopoiesis show 43 
that compound Npm1
cA/+
;Nras
G12D/+ 
or Npm1
cA
;Flt3
ITD
 share a number of features: Hox gene 44 
over-expression, enhanced self-renewal, expansion of hematopoietic progenitors and 45 
myeloid differentiation bias. However, Npm1
cA
;Flt3
ITD
 mutants, displayed significantly higher 46 
peripheral leucocyte counts, early depletion of common lymphoid progenitors and a 47 
monocytic bias compared to the granulocytic bias in Npm1
cA/+
;Nras
G12D/+ 
mutants. 48 
Underlying this was a striking molecular synergy manifested as a dramatically altered gene 49 
expression profile in Npm1
cA
;Flt3
ITD
, but not Npm1
cA/+
;Nras
G12D/+
, progenitors compared to 50 
wild type. Both double-mutant models developed high penetrance AML although latency 51 
was significantly longer with Npm1
cA/+
;Nras
G12D/+
. During AML evolution, both models 52 
acquired additional copies of the mutant Flt3 or Nras alleles, but only Npm1
cA/+
;Nras
G12D/+ 
 53 
mice showed acquisition of other human AML mutations, including IDH1 R132Q. We also 54 
find, using primary Cas9-expressing AMLs, that HoxA genes and selected interactors or 55 
downstream targets are required for survival of both types of double-mutant AML. Our 56 
results show that molecular complementarity underlies the higher frequency and 57 
significantly worse prognosis associated with NPM1c/FLT3-ITD versus NPM1/NRAS-G12D-58 
mutant AML and functionally confirm the role of HOXA genes in NPM1-driven AML.  59 
 60 
[247 words] 61 
 62 
 63 
  64 
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Introduction 65 
Advances in genomics have defined the somatic mutational landscape of acute myeloid leukemia 66 
(AML), leading to a detailed characterisation of their prognostic significance and patterns of mutual 67 
co-occurrence or exclusivity. 
1,2
 Mutations in NPM1, the gene for Nucleophosmin, characterise the 68 
most common subgroup of AML representing 25-30% of all cases, result in cytoplasmic dislocation of 69 
the protein (NPM1c) and are mutually exclusive of leukemogenic fusion genes.
1-3
 As is often the case 70 
for fusion genes, progression to AML after the acquisition of mutant NPM1 is contingent upon the 71 
gain of additional somatic mutations such as those that activate STAT and/or RAS signalling
3,4
. For 72 
reasons that are not clear, this transforming step favours acquisition of internal tandem duplications 73 
in FLT3 (FLT3-ITD) over other somatic mutations with similar effects such as those involving NRAS or 74 
KRAS.
1-4
 Furthermore, the NPM1c/FLT3-ITD combination is associated with a significantly worse 75 
prognosis compared to combinations of NPM1c with mutant NRAS, KRAS or other mutations.
2
 76 
Whilst the adverse prognostic impact of NPM1/FLT3-ITD vs NPM1/RAS co-mutation influences 77 
clinical decisions in AML, its molecular basis and that of the frequent co-occurrence of NPM1c and 78 
FLT3-ITD in AML are unknown. Here, in order to investigate these phenomena, we compare the 79 
interaction of Npm1c with Flt3-ITD to its interaction with Nras
G12D
 in knock-in mice. Individually, 80 
knock-in models of NPM1c, FLT3-ITD and NRAS-G12D display enhanced myelopoiesis and 81 
progression to myeloproliferative disorders or AML in a significant proportion of animals.
5-7 
Also, we 82 
and others have previously shown that Npm1c and Flt3-ITD synergise to drive rapid-onset AML
8,9
, 83 
but the interaction between Npm1c and mutant Nras
G12D
 has not, to our knowledge, been previously 84 
investigated in knock-in mice
10
. Our findings reveal that the combination of Npm1c and Flt3-ITD has 85 
an early profound effect on gene expression and hematopoiesis, whilst Npm1c and Nras-G12D 86 
display only modest molecular synergy and subtler cellular changes. Also, whilst both types of co-87 
mutation drove AML in the majority of mice, the leukemias in Npm1c;Flt3-ITD mice were more 88 
aggressive and undifferentiated than those which developed in Npm1c;Nras-G12D animals. At the 89 
genomic level, there was frequent amplification in both  models of the mutant Flt3-ITD or Nras-90 
G12D allele, however additional somatic mutations in AML driver genes (e.g. Idh1 and Ptpn11) were 91 
seen only in  Npm1c;Nras-G12D AMLs. Our findings propose that the molecular synergy between 92 
Npm1c and Flt3-ITD underpin the co-occurrence patterns, phenotype and prognosis of NPM1-93 
mutant AML. 94 
 95 
 96 
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Materials and methods 97 
Animal husbandry 98 
Mx1-Cre+;Npm1
flox-cA/+
 were crossed with Nras
LSL-G12D
 or Flt3
ITD
 mice, to generate triple transgenic 99 
animals (Mx1-Cre;Npm1
flox-cA/+
;Nras
LSL-G12D/+
 and Mx1-Cre;Npm1
flox-cA/+
;Flt3
ITD/+
). To activate 100 
conditional alleles (Npm1
cA
 and Nras
G12D
) in approximately 12-14 week old Mx1-Cre;Npm1
flox-
101 
cA/+
;Nras
LSL-G12D/+ 
mice, Mx1-Cre was induced by administration of pIpC. As described previously, Mx-1 102 
Cre;Npm1
Flox-cA/+
;Flt3
ITD/+
 mutants do not require pIpC induction of Mx1-Cre and recombination of the 103 
Npm1
flox-cA 
allele.
8
 For pre-leukemic analyses Npm1
cA/+
;Nras
G12D/+
 were sacrificed 4-5 weeks post pIpC 104 
and Npm1
cA/+
;Flt3
ITD/+
 were sacrificed at 5 weeks of age. Genotyping for mutant alleles was 105 
performed as previously described.
5-7
 All animal procedures were carried out in accordance with the 106 
Home Office Animals (Scientific Procedures) Act 1986 Amendment Regulations (2012) under project 107 
license 80/2564. 108 
Hematological measurements 109 
Blood counts were performed on a VetABC analyzer (Horiba ABX). 110 
Histopathology 111 
Formalin fixed, paraffin embedded (FFPE) sections were stained with hematoxylin and eosin. 112 
Samples from leukemic mice were also stained with anti-CD3, anti-B220 and anti-myeloperoxidase. 113 
All material was examined by two experienced histopathologists (P.W. and M.A.) blinded to mouse 114 
genotypes.  115 
Colony-forming assays and serial re-plating 116 
Nucleated cells (3 x10
4
) from bone marrow (BM) aspirates of mutant and wild-type mice were 117 
suspended in cytokine-containing methylcellulose-based media (M3434, Stem Cell Technologies) 118 
and plated in duplicate wells of 6-well plates. Colony-forming units (CFUs) were counted 7 days later. 119 
For serial re-plating, 3 x10
4 
cells were re-seeded and colonies counted after 7 days. 120 
Flow cytometry and cell sorting 121 
Single cell suspensions of BM cells or splenocytes were incubated in 0.85% NH
4
Cl for 5 minutes to 122 
lyse erythrocytes. Cells were then suspended in Hank's Balanced Salt Solution (HBSS) supplemented 123 
with 2% FCS and 10µM HEPES. Progenitor populations were defined and stained as described in 124 
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supplementary methods. Gated cellularity was calculated by multiplying the percentage of gated 125 
cells by the total number of nucleated cells from BM samples after erythrocyte depletion.  126 
Viral transduction of BM progenitors and AML cell culture. 127 
Lineage depleted BM aspirates, isolated from wildtype and Flt3
ITD/+
 mice, were transduced with 128 
MSCV-Hoxa9-GFP and/or MSCV-Nkx2-3-CFP retroviruses and expanded for 7 days in liquid culture 129 
(X-Vivo, Lonza, supplemented with 10ng/ml IL-3, 10ng/ml IL-6 and 50ng/ml SCF, Peprotech). CFP, 130 
GFP or double positive cells were FACS sorted and 2.5 x10
4
 cells re-plated in semi-solid media as 131 
previously described. BM-derived AML cells from Roas26-EF1-Cas9 mice were cultured in vitro in the 132 
presence of cytokines. Disruption of individual candidate genes was performed by transduction with 133 
lentivirus expressing gene-specific guide RNA (gRNA) and blue fluorescent protein (BFP). The impact 134 
of gene disruption on AML cell growth was determined using competitive co-culture of transduced 135 
(BFP+) vs non-transduced (BFP-) cells as described previously
11
 (Figure 6A, Supplemental methods).  136 
Microarray and comparative genomic hybridization analysis 137 
Mouse gene expression profiles (GEPs) were generated using the Illumina MouseWG-6 v2 Expression 138 
BeadChip platform (Illumina). DNA copy number variation in leukemic samples was assessed with 139 
Mouse Genome Comparative Genomic Hybridization 244K Microarray (acGH, Agilent Technologies). 140 
Full details of analysis are provided in supplemental methods. For mouse gene expression profiling, 141 
n=4-10 (Lin
-
) or n=3-5 (MPP).  142 
AML exome sequencing and mutation calling 143 
Whole exome sequencing (WES) of AML BM and control C57BL/6N or 129Sv tail DNA was performed 144 
using the Agilent SureSelect Mouse Exon Kit (Agilent Technologies) and paired-end sequencing on a 145 
HiSeq2000 sequencer (Illumina). Validation of mutations was performed using MiSeq sequencing 146 
(Illumina) of amplicon libraries as previously described (See Supplemental Methods Figure S1 and 147 
Supplemental Tables 6 and 7 for primer sequences).
12,13
 Full details of analysis are provided in 148 
supplemental methods. 149 
Datasets  150 
Microarray data were deposited at Array Express (accession number E-MTAB-5356), and RNA 151 
sequencing (accession numbers ERS1732539 to ERS1732546, ERS812461 and ERS812462) as well as 152 
exome and Miseq sequencing (accession numbers PRJEB18526 and ERP020464) at EBI ENA. 153 
 154 
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Results 156 
Mutant Npm1 co-operates with Nras-G12D
 
and Flt3-ITD to increase self-renewal of hematopoietic 157 
progenitors and expand myelopoiesis 158 
To understand the impact of the studied mutations, we analyzed hematopoietic cell compartments 159 
of Npm1
cA/+
;Nras
G12D/+
, Npm1
cA/+
;Flt3
ITD/+
, Nras
G12D/+
, Flt3
ITD/+ 
and wild type (WT) mice 4-6 weeks after 160 
activation of conditional mutations (Figure 1). Compared to Flt3
ITD/+ 
single
 
mutants, Npm1
cA/+
;Flt3
ITD/+
 161 
mice displayed higher white cell counts (WCC) (56±13.4 vs 6.5±0.5 x10
6
 g/L, p<0.001) and spleen 162 
weights (0.63g vs 0.16g, p<0.001), but not BM cellularity (Figure 1B). By contrast, both Nras
G12D/+
 and
 
163 
Npm1
cA/+
;Nras
G12D/+
 mutants exhibited subtler increases in spleen weight (WT: 0.12g, Nras
G12D/+
: 164 
0.18g, Npm1
cA/+
;Nras
G12D/+
:
 
0.19g, p<0.01 and p<0.001 respectively), but increased  BM cellularity  165 
(WT: 28.1±1.9 x10
6
, Nras
G12D/+
: 43.7±2.6 x 10
6 
and Npm1
cA/+
;Nras
G12D/+
:
 
41.3±3.2 x10
6
, p<0.01 for 166 
either comparison vs WT) (Figure 1B). 167 
Expanded myelopoiesis and myeloproliferation were previously documented in single Nras
G12D/+
 and 168 
Flt3
ITD/+
 mutant mice.
5,6
 Mutant Npm1 augmented these phenotypes with increases in total Mac-1
+
 169 
splenocytes (from 27% to 50% for Nras
G12D/+
; and 57% to 73% for Flt3
ITD/+
). Notably, these cells were 170 
predominantly granulocytic (Mac-1
+
/Gr-1
+
) in Npm1
cA/+
;Nras
G12D/+ 
and predominantly monocytic 171 
(Mac-1
+
/Gr-1
-
) in Npm1
cA/+
;Flt3
ITD/+
 mice (Supplemental Figure S1A).   172 
Nras
G12D/+ 
mice have been shown to have increased hematopoietic stem (HSC) and progenitor cell 173 
numbers, due to increased proliferation and self-renewal of the HSC and multipotent progenitor 174 
(MPP) compartments.
14,15 
Our results confirm these data demonstrating significant increases in total 175 
myeloid progenitors i.e. granulocyte-macrophage (GMP) and common-myeloid progenitors (CMP). 176 
Total numbers of Sca-1/Kit positive early progenitors (LSK) and MPPs are also increased in both 177 
Npm1
cA/+
;Nras
G12D/+ 
and Nras
G12D/+
 BM cells (Figure 1C and Supplemental Figure S2A). However, 178 
Nras
G12D/+
 progenitor cell composition was largely unaltered by the addition of mutant NPM1. 179 
Concordant with previous studies, hematopoiesis in Flt3
ITD/+
 mice was characterised by increased 180 
numbers of total myeloid progenitors (LK p<0.05 and GMPs p<0.01) and early progenitor 181 
populations (LSK, MPP and LMPP, p<0.01, p<0.01 and p<0.05 respectively) (Figure 1C and 182 
Supplemental Figure S2A).
 16,17 
Of note, there were detectable decreases in the size of the common 183 
lymphoid progenitor (CLP) population in Flt3
ITD/+
 and Npm1
cA/+
;Flt3
ITD/+
 mice (Figure 1C) (in part due 184 
to the reduction in Il-7Rα-positive cells) (Figure S2B). Npm1
cA/+
;Flt3
ITD/+
 mice also exhibited robust 185 
increases in numbers of LK, LSK, MPP and LMPP populations, above what was observed with Flt3
ITD/+
, 186 
when compared to WT. In direct comparison with Flt3
ITD/+
 mutants, numbers of CMP and MEP 187 
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progenitors in Npm1
cA/+
; Flt3
ITD/+
 mice were reduced (from 55x10
3
 to 16x10
3
, p<0.05 and from 61x10
3
 188 
to 17x10
3
, p<0.05), yet GMPs, proposed as direct descendants of CMPs
18
, are significantly increased. 189 
This demonstrates that Flt3
ITD/+
 mutant myelopoiesis is dramatically altered by the addition of 190 
Npm1
cA/+
. In direct comparison with Npm1
cA/+
;Nras
G12D/+
, Npm1
cA/+
;Flt3
ITD/+
  mice showed increased 191 
LMPP and  GMP populations with reduced numbers of lymphoid progenitors (CLP) (Figure 1E). 192 
In order to assess the effects on the earliest detectable hematopoietic stem cell compartment (HSC) 193 
we opted to perform E-SLAM staining (CD45
+
/EPCR
+
/CD48
-
/CD150
+
).
19
 Importantly, this does not rely 194 
on cell surface expression of FLT3, and reveals the percentage of E-SLAM detectable HSCs is 195 
decreased in Npm1
cA/+
;Nras
G12D/+
 mice and further so in Npm1
cA/+
;Flt3
ITD/+
mutants (Figure 1D). Finally, 196 
using serial re-plating of BM cells in semi-solid media we show that Npm1
cA/+
 co-mutation markedly 197 
increased self-renewal of Flt3
ITD/+
 (as shown previously 
8
) and of Nras
G12D/+
 cells (Figure 1F).  198 
An Npm1
cA/+
 transcriptional signature persists in double mutant hematopoietic progenitors  199 
To examine their combined effects on transcription we performed comparative global gene 200 
expression profiling of lineage negative (Lin
-
) BM cells using microarrays. Npm1
cA/+
;Nras
G12D/+ 
and 201 
Npm1
cA/+
;Flt3
ITD/+
 cells displayed a dramatically altered
 
GEP compared to single Nras
G12D/+
  or Flt3
ITD/+
 202 
mutants (Figure 2A and Supplemental Figure S3B). Previously, we showed that mouse Npm1
cA/+
 Lin
- 
203 
cells overexpressed several homeobox (Hox) genes (in particular overexpression of Hoxa5, Hoxa7, 204 
Hxa9 and two other homeobox genes, Hopx and Nkx2-3).
7
 Here, we show that this signature, absent 205 
from Nras
G12D/+ 
or Flt3
ITD/+
 singular mutant mice, persists in compound Npm1
cA/+
;Nras
G12D/+ 
and
 
206 
Npm1
cA/+
;Flt3
ITD/+
 Lin
-
 progenitors. (Figure 2A, Supplemental Figure S3A-C). Gene Set Enrichment 207 
Analysis (GSEA) of Npm1
cA/+ 
single and compound mutant cell GEPs, showed significant enrichment 208 
for genes up-regulated in NPM1-mutant and MLL-fusion gene positive human leukemias (Figure 2A).  209 
Overexpression of the homeobox gene NKX2.3 in human NPM1-mutant AML 210 
Using the human TCGA AML dataset, we compared GEPs of NPM1 mutant (NPM1c
+ve
) to NPM1 211 
wildtype (NPM1
wt
) AML.
1
 In agreement with previously published analyses, both HOXA and HOXB 212 
genes were significantly overexpressed in NPM1c
+ve
 AML (Figure 2B).
20
 We also noted NKX2-3 was 213 
also overexpressed in keeping with our findings in Npm1
cA/+
 mice (Figure 2A). Recently, NKX2-3 214 
overexpression was shown to be the most effective discriminant of MLL-MLLT4 (MLL-AF6)-driven 215 
AML from AMLs driven by other MLL-fusion genes.
 21
 Whilst overexpression of Hox genes such as 216 
Hoxa9 has been shown to impart increased self-renewal and proliferation of hematopoietic 217 
progenitors, the effects of Nkx2-3 overexpression are unknown.
 22 
To study this we performed 218 
retroviral gene transfer of fluorescently tagged Nkx2-3-CFP and Hoxa9-GFP into wildtype and Flt3
ITD/+ 
219 
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Lin
- 
cells. Cells were subsequently sorted and plated in semi-solid methylcellulose for colony 220 
formation assays (Figure 2Ci). We find that overexpression of Nkx2-3 increases clonogenic potential, 221 
albeit to a lesser extent compared to Hoxa9 overexpression, in both wildtype and Flt3
ITD/+
 222 
progenitors. Notably, this is not augmented in combined transfected cells. (Figure 2Cii).  223 
Hoxa gene expression is unaltered in mutant NPM1 early multipotent progenitors 224 
In order to mitigate the impact of the studied driver mutations on cell surface phenotypes, we 225 
performed transcriptome analysis on a homogeneous population of early progenitors, purified LSK- 226 
MPPs, (Figure 2D). Hox gene expression was not significantly altered in this population in any of the 227 
Npm1
cA/+
 models when compared to wildtype or single Nras
G12D/+
 and Flt3
ITD/+
 mutants (Figure 2E and 228 
Figure S3C). These results are in agreement with observations that Hox gene expression in human 229 
NPM1c AML blasts is comparable to that seen in WT human HSCs and myeloid progenitors.
20 
As we 230 
do not observe statistically significant expansion in total (Lin
-
) progenitors in single Npm1
cA/+ 
mice 231 
(figure 1C), these data propose that, unlike HSCs, the observed pattern of Hox overexpression in 232 
these progenitors is a molecular consequence of NPM1c rather than a change in cellular 233 
composition. This concurs with our published observations that the Hox signature is detectable even 234 
in CD19-positive B-cells
7
. 235 
MPPs from single Nras
G12D/+ 
or Flt3
ITD/+
 and the respective Npm1
cA/+
 compound mutant MPPs also had 236 
distinct transcriptional changes. Compared to WT, both Nras
G12D/+
 and Npm1
cA/+
;Nras
G12D/+
 MPPs 237 
displayed small numbers of differentially expressed genes yet only ~20% of these were shared 238 
(Figure 2Di). GSEA did not uncover significant overlap with any pre-established expression signatures 239 
(data not shown). In contrast, the “addition” of Npm1
cA/+ 
to Flt3
ITD/+
 in MPPs led to differential 240 
expression of a large number of additional genes, whilst also retaining most of the transcriptional 241 
changes attributable to Flt3
ITD/+
 (Figure 2Dii, Table S2) demonstrating the powerful synergy between 242 
Npm1
cA/+ 
and Flt3
ITD/+
. Pathway analysis of genes differentially expressed in Npm1
cA/+
;Flt3
ITD/+
 MPPs 243 
revealed enrichment of genes in the JAK-STAT pathway (Supplemental Figure 3E, Supplemental 244 
Tables S4), including the negative regulators Cish and Socs2 (Figure 2F). A number genes, encoding 245 
proteins involved in MAPK signaling were also deregulated, as were genes involved in chromatin 246 
regulation/organisation and hematopoietic/myeloid differentiation (Figure 2F, Supplemental Figure 247 
3D). Many of the genes in our Npm1
cA/+
;Flt3
ITD/+
 dataset were also found deregulated in a recently 248 
published Tet2
-/-
;Flt3
ITD/+
 mouse model of AML
 
(, Supplemental Figure 3F and Supplemental Table 6,) 249 
which serves to verify our mouse dataset technically, but also reveals a distinguishing expression 250 
signature of FLT3-ITD which includes Socs2, Id1, Csfr3r and Bcl11a.
17
 In contrast a lack of correlation 251 
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between deregulated gene sets of Npm1
cA/+
;Flt3
ITD/+
 and Npm1
cA/+
;Nras
G12D/+ 
MPPs (Supplemental 252 
Figure S3D) emphasises the molecular distinction between these compound mutants.  253 
Npm1
cA/+
 and Nras
G12D
 collaborate to promote high penetrance AML 254 
To understand the leukemogenic potential of combined Npm1
cA/+
 and Nras
G12D
 mutations, we aged 255 
combined and single mutant cohorts. Compound Npm1
cA/+
;Nras
G12D/+
 and Npm1
cA/+
;Flt3
ITD/+
 mice had 256 
significantly reduced survival (median 138 and 52.5 days respectively) when compared to wildtype 257 
(618 days), Npm1
cA/+ 
(427 days), Nras
G12D/+ 
(315 days) and Flt3
ITD/+ 
(also 315 days) (Figure 3A, 258 
Supplemental Figure S4A). No difference in the survival of Nras
G12D/+
 and Flt3
ITD/+
 mutant mice was 259 
observed (p=0.85, see Supplemental Figure S4A for all comparisons). At time of sacrifice, blood 260 
counts and tissues were collected and subjected to histopathological analysis. Aged 261 
Npm1
cA/+
;Nras
G12D/+
 and Npm1
cA/+
;Flt3
ITD/+
 mice exhibited characteristic AML pathological findings at a 262 
much higher frequency than single mutant mice. These included significantly higher WCC, reduced 263 
platelet numbers and substantial organ infiltration with leukemic cells (Supplemental Figure S4B-D). 264 
Histological analysis verified the increased AML incidence from 41% (Flt3
ITD/+
) to 100% in 265 
Npm1
cA/+
;Flt3
ITD/+
 samples and from 13% (Nras
G12D/+
) to 85% in Npm1
cA/+
;Nras
G12D/+
 samples (45% AML 266 
with maturation, AML
+
 and 40% AML without maturation, AML
-
 as defined by the Bethesda 267 
classification
23
 (Figure 3B).  268 
Additional somatic mutations are required for progression to AML in Npm1
cA/+
; Nras
G12D/+
 mice. 269 
Npm1
cA/+
;Flt3
ITD/+ 
mice succumb to AML significantly more rapidly, compared to Npm1
cA/+ 
and 270 
Npm1
cA/+
;Nras
G12D/+
mice. We hypothesised that the slower onset of AML in the latter two genotypes 271 
may be due to the requirement for additional cooperating mutations. To test this, we performed 272 
aCGH and WES of AMLs from Npm1
cA/+
, Npm1
cA/+
;Flt3
ITD/+
and Npm1
cA/+
;Nras
G12D/+
 mice. We first 273 
confirmed the frequent development of loss-of-heterozygosity (LOH) at the Flt3 locus in 274 
Npm1
cA/+
;Flt3
ITD/+
 AMLs 
8,24
 and verified this by quantifying Flt3
ITD 
variant allele fractions (VAFs) using 275 
PCR-MiSeq (Figure 4Ai). aCGH showed that LOH was copy-neutral and due to uniparental disomy of 276 
Flt3
ITD
 (Supplementary Figure 4Aii). Interestingly, aCGH of Npm1
cA/+
;Nras
G12D/+
 samples revealed 277 
amplification of chr3 in 5/10 samples tested (Figure 4Bi). This was exclusive to Npm1
cA/+
;Nras
G12D/+
 278 
AMLs and mapped to a minimally amplified region (chr3: 102743581-103470550) containing Nras 279 
(Supplementary Table S10). We confirmed these Nras
G12D
copy gains using PCR-MiSeq and also found 280 
copy neutral LOH for Nras
G12D
 in 3/10 AMLs. In addition, we found copy neutral LOH in 3 of 4 281 
Npm1
cA/+
;Nras
G12D/+
 AMLs not studied by aCGH. In summary, increased Nras
G12D
 dosage was detected 282 
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in 11/14 Npm1
cA/+
;Nras
G12D/+
 AMLs (Figure 4Bii), and this correlated with levels of RAS pathway 283 
activation as measured by pERK1/2 staining  (Figure 4C). 284 
WES revealed that the average number of single nucleotide variants (SNVs) and small 285 
insertions/deletions (indels) per AML sample correlated positively to survival (Figure 5A). Npm1
cA/+
 286 
AMLs spontaneously acquired mutations in genes involved in RAS signaling (Nras-p.Q61H, Cbl-287 
p.S374F, Ptpn11-p.S502L, Nf1-p.W1260* and Nf1-R683*) confirming this genetic interaction.  288 
Likewise, we detected a spontaneous tyrosine kinase domain mutation in Flt3, (Flt3-p.D842G) 289 
confirming the importance of FLT3 mutations in progression of NPM1-mutant AML (Figure 5B-C, 290 
Supplemental Table 9). Interestingly, a single Npm1
cA/+
;Nras
G12D/+
 AML harbored an Idh1-p.R132Q 291 
mutation and mirroring the R132H/R132C
 
 mutations commonly seen in human AML
1
 whilst IDH1-292 
R132Q itself was reported in human chondrosarcoma.
25 
aCGH also revealed complete or partial gain 293 
of a minimally amplified region on chr7 in 7/8 Npm1
cA/+ 
and 4/9 Npm1
cA/+
;Nras
G12D/+
 AMLs containing 294 
genes implicated in leukemogenesis including Nup98, Wee1 and Eed, (Supplemental Figure S5C).
7,26-
295 
28 
Single copy loss of a region containing the epigenetic modifiers Wt1, Asxl1, Dnmt3a (1/8 Npm1
cA/+
) 296 
and a focal deletion of Ezh2 (1/9 Npm1
cA/+
; Nras
G12D/+
) were also detected (Figure 5C and 297 
Supplemental Figure S5C). 298 
MLL, Hox genes and their partners are required for the survival of Npm1
cA
-driven AML cells. 299 
To assess their contribution to AML maintenance in Npm1
cA/+
;Nras
G12D/+
 and Npm1
cA
;Flt3
ITD
 mice, we 300 
employed CRISPR-Cas9 to disrupt selected deregulated genes identified by our pre-leukemic GEP, 301 
studies. For this, we bred with Rosa26-EF1-Cas9 animals
11
 to generate 302 
Rosa26
Cas9/+
;Npm1
cA/+
;Nras
G12D/+
; and Rosa26
Cas9/+
;Npm1
cA/+
;Flt3
ITD/+
 mice. Competitive co-culture of 303 
gRNA transduced and non-transduced BM cells from these mice revealed that Hoxa10 and to a 304 
lesser degree Hoxa9, but not Hoxa7 are required for Npm1
cA/+
;Nras
G12D/+
 and Npm1
cA
;Flt3
ITD/+
 AML 305 
maintenance (Figure 6B). In contrast, all three HoxA genes were required for growth of AMLs 306 
generated by retroviral MLL-AF9 transformation of Flt3
ITD/+
 BM cells (Supplementary Figure 307 
S7C).
11,29,30
 Notably, although Nkx2-3 overexpression enhanced colony-forming ability of wild type 308 
and Flt3
ITD/+
 BM (Figure 2C), disruption of endogenous Nkx2-3 did not significantly affect 309 
proliferation of Npm1
cA/+
;Nras
G12D/+
 or Npm1
cA
;Flt3
ITD/+
 AMLs in vitro. Other genes whose disruption 310 
reduced proliferation of Npm1cA-driven AMLs included Mll (Kmt2a) gene, recently shown to be a 311 
therapeutic target in this AML type
31
,  Hoxa9/10 partners or co-factors including Meis1, Pbx1 and 312 
Pbx3, the HOXA9 targets Bcl2 and Lmo2
32-34
. A number of genes with altered expression in mutant 313 
pre-leukemic MPP cells, were not required for survival of AML cells in vitro (Figure 6C).  However, we 314 
cannot exclude a potential role for these in leukemia initiation.  315 
We also wanted to investigate potential differences in JAK/STAT vs RAS signaling in our AMLs in a 316 
similar way. FLT3-ITD leads to constitutive activation of JAK/STAT signaling, driving growth and 317 
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transformation of hematopoietic cells
35-37
. In keeping with this, our transcriptome analysis revealed 318 
that genes involved in JAK/STAT signaling (Stat5a, Cish, Socs2) were differentially expressed in 319 
Npm1
cA
;Flt3
ITD
  but not in Npm1
cA
;Nras
G12D
 Lin
-
 progenitors. Nevertheless, CRISPR-targeting of Jak2 320 
and Stat5a/b genes inhibited the growth of both Npm1
cA
;Flt3
ITD/+
 and Npm1
cA/+
;Nras
G12D/+
 AML cells 321 
(Supplemental Figure S8B). We confirmed by RNA-seq that this was due to activation of a JAK/STAT 322 
programme in Npm1
cA/+
;Nras
G12D/+ 
AML cells (Figure S9). In this light we conclude that the cytokines 323 
required for culturing primary AML cells in vitro (IL-3, IL-6 and SCF), precludes the assessment of 324 
signaling genes in AML growth and proliferation.  325 
 326 
Discussion 327 
Whilst the mutational drivers of AML and their patterns of co-occurrence are well understood, the 328 
molecular basis for the frequency and prognostic impact of these patterns remain unknown. Of 329 
particular clinical relevance are the co-occurrence patterns of mutant NPM1 mutations, which 330 
characterize the most common AML subtype
1,2
. Co-mutation of NPM1 with FLT3-ITD is both 331 
significantly more frequent and carries a worse prognosis than co-mutation with RAS genes.
1,2
 To 332 
understand the basis of this observation we investigated the interactions of these mutations in 333 
bespoke experimental models (Figure 1A).  Analysis of the short-term impact of these mutations on 334 
hematopoiesis confirmed that single Npm1
cA/+
 mutant mice have normal BM cellularity, WCC and 335 
splenic weight.
7
 As described before, single Flt3
ITD/+
 and Nras
G12D/+
 had moderate but significant 336 
increases in splenic size, whilst Nras
G12D/+ 
had raised WCC and BM cellularity.
5,6 
Introduction of 337 
Npm1
cA/+
 into the Nras
G12D/+
 background did not alter these parameters significantly, yet the 338 
Npm1
cA/+
;Flt3
ITD/+
 co-mutation led to a dramatic rise in WCC and splenic size(Figure 1B). At the 339 
cellular level, the Npm1
cA/+
;Nras
G12D/+
 combination did not change progenitor and stem cell numbers 340 
when compared to Nras
G12D/+
 alone. In contrast, when compared to Flt3
ITD/+
 mutants, 341 
Npm1
cA/+
;Flt3
ITD/+
 mice displayed reductions in CMP and MEP, and increases in LSK progenitors. 342 
Furthermore, Npm1
cA/+
;Flt3
ITD/+
 mice showed a profound reduction in phenotypic HSCs (Figure 1 C–343 
E).  344 
The differential impact of Npm1
cA/+ 
on Flt3
ITD/+
 versus Nras
G12D/+
 was reflected in marked differences 345 
in GEPs between double mutant mice. The Npm1
cA/+
;Nras
G12D/+
 model displayed only minimal 346 
differences to single Nras
G12D/+
, whilst Npm1
cA/+
;Flt3
ITD/+
 lin
-
 progenitors had profoundly different 347 
GEPs to Flt3
ITD/+
. From these and complimentary analyses of human NPM1c AML we identify NKX2-3 348 
as a marker of this type of AML. Expression of NKX2-3 distinguishes MLL-AF6 and MLL-ENL from 349 
other forms of MLL-mutant leukemia
21,38
, highlighting the mechanistic links between NPM1c- and 350 
MLL-fusion genes. Here, we show that whilst potent overexpression of Nkx2.3 by lentivirus may have 351 
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an impact on self-renewal, genetic disruption of the endogenous Nkx2.3 did not inhibit AML cell 352 
growth (Figure 6). 353 
We went on to age double mutant mice and report that, like Npm1
cA/+
;Flt3
ITD/+
 animals, 354 
Npm1
cA/+
;Nras
G12D/+
 mice also develop highly penetrant AML, albeit with a much longer latency and a 355 
more mature phenotype overall. Interestingly single mutant Flt3
ITD/+ 
and Nras
G12D/+
 mice had similar 356 
survival (Figure 3A), indicating that the interaction with Npm1
cA 
was central to this difference. To 357 
understand the genetic events involved in leukemic progression, we performed exome sequencing 358 
and copy number analysis of Npm1
cA/+
;Flt3
ITD/+
 and Npm1
cA/+
;Nras
G12D/+ 
AMLs. Interestingly, the 359 
commonest somatic event during AML progression was an increase in Nras
G12D/+
 or Flt3
ITD/+
 mutant 360 
allele burden, through copy-neutral LOH or copy number gain. In human AML, copy-neutral LOH is 361 
common for FLT3-ITD, but less so for mutant NRAS; for example in a recent study we identified only 362 
one such LOH event amongst 13 RAS mutant human AMLs.
13
 Nevertheless, in keeping with our 363 
findings, studies using the Nras
G12D/+
 model, in combination with retroviral insertional mutagenesis, 364 
resulted in high penetrance AML with frequent LOH for Nras-G12D when combined with 365 
overexpression of oncogenes such as Evi1.
6,39
 The different incidence of LOH for mutant RAS 366 
between murine and human AML may operate through the fact that, compared to the acquisition of 367 
other oncogenic mutations (e.g. Idh1-R132Q in our study), LOH for Nras-G12D may be more 368 
expedient in mice given the large numbers of Npm1
cA/+
/Nras
G12D/+
 pre-leukemic HSCs. Other possible 369 
reasons may relate to the differences in human-mouse synteny and the fact that mice are inbred 370 
potentially making recombination events more likely.  Notwithstanding mouse-human differences in 371 
LOH frequencies, our data provide strong evidence that increased mutant Flt3 and Ras gene dosage 372 
are important for leukemic transformation/progression. 373 
Finally, in order to investigate their role in Npm1c AML, we use CRISPR-Cas9 to disrupt selected 374 
genes in Cas9-expressing primary mouse leukemia cells. Using this approach we confirmed the 375 
requirement for the HoxA9/10 functional gene network in Npm1c AML maintenance. Interestingly, 376 
although it is widely appreciated that overexpression of Hoxa9 stimulates leukemic transformation 377 
22,29,33
, in our model disruption of Hoxa10 has a more detrimental impact on survival, mirroring our 378 
recent genome wide essentiality screen in the NPM1c-harboring OCI-AML3 cell line.
11
  379 
Our study describes the first faithful mouse model of the interaction of Npm1c with Nras-G12D, the 380 
preferred form of oncogenic NRAS in human AML.
2
 Both NPM1c models share a number of salient 381 
characteristics, which are imparted by mutant Npm1, such as homeobox gene overexpression and 382 
increased self-renewal of hemopoietic progenitors. However, we demonstrate that the co-383 
occurrence of Npm1c/Flt3-ITD is significantly more leukemogenic and leads to strikingly different 384 
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molecular and cellular consequences compared to Npm1c/Nras-G12D, providing a mechanistic 385 
explanation for the higher frequency and worse prognosis of NPM1c/ FLT3-ITD AML. Furthermore, 386 
through the generation of Cas9-expressing AML models, we also present a versatile approach for the 387 
study of genetic interactions in primary mouse leukemias using CRISPR. Whilst our non-Cas9-388 
expressing Npm1c/Flt3-ITD model was helpful in recent studies of new anti-AML therapies
31
, these 389 
Cas9-expressing models can be utilized to study both genetic and pharmacological interactions in 390 
parallel, and also to perform targeted mechanistic studies. 391 
[3966 words] 392 
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 422 
Figure Legends 423 
Figure 1. Mutant Npm1 co-operates with Nras-G12D and Flt3-ITD to enhance myeloid 424 
differentiation and enhance progenitor self-renewal.  425 
(A) Schema for Mx-1 Cre, Npm1
flox-cA
, Nras
LSL-G12D 
and Flt3
ITD
 inter-crosses. (B) Nras
G12D/+
 mice show a 426 
subtle and Npm1
cA/+
; Flt3
ITD/+
 mice a marked increase in white cell count (WCC), compared to 427 
wildtype. Splenic sizes were significantly increased in all mutant genotypes except Npm1
cA/+
, with 428 
Npm1
cA/+
; Flt3
ITD/+
 showing the most striking phenotype. Bone marrow cellularity was increased only 429 
in the presence of the Nras
G12D/+
 allele.  (C) FACS analysis at 4-5 weeks after mutation induction. 430 
Gating strategies depicted are from wildtype mice. Significant differences in the stem and progenitor 431 
cell compartments of Nras
G12D/+
 and Flt3
ITD/+, 
but not Npm1
cA/+
 single mutant mice, as previously 432 
reported. In double mutant mice, the Npm1
cA/+
; Nras
G12D/+
 combination was not significantly 433 
different to Nras
G12D/+
, in contrast to Npm1
cA/+
;Flt3
ITD/+
 which was markedly different to both Flt3
ITD/+
 434 
and Npm1
cA/+
 single mutants. (D) Using a cell surface phenotype independent of FLT3 staining, we 435 
found that CD45+/EPCR+/CD150+/CD48- HSCs were reduced slightly in Npm1
cA/+
;Nras
G12D/+
 and 436 
markedly in Npm1
cA/+
;Flt3
ITD/+
mice. (E) Summary of hematopoietic effects of Npm1
cA/+
;Nras
G12D/+
 and 437 
Npm1
cA/+
;Flt3
ITD/+
 double mutations in mice. LK, Lin
-
/Kit
+
; LSK, Lin
-
/Sca-1
+
/Kit
+
; CMP, common myeloid 438 
progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-monocyte progenitor; 439 
MPP, multi-potent progenitor; LMPP, lymphoid primed multi-potent progenitor; CLP, common 440 
lymphoid progenitor and HSC, hematopoietic stem cell. (F) Single Npm1
cA/+
 and double 441 
Npm1
cA/+
;Nras
G12D/+
 or Npm1
cA/+
;Flt3
ITD/+ 
mutant
 
hematopoietic progenitors show increased self-442 
renewal potential in whole bone marrow serial replating assays  (n=4-8). Mean ±SEM are plotted. 443 
Significant values are reported for one-way analysis of variance (ANOVA, Bonferroni adjusted); (* 444 
P<0.05 vs wildtype, ** P<0.01 vs wildtype, *** P<0.001 vs wildtype), (Δ P<0.05 vs Flt3ITD/+, 445 
ΔΔ  P<0.01 vs Flt3ITD/+, ΔΔΔ  P<0.001 vs Flt3ITD/+), (♣ P<0.05 vs NrasG12D/+, ♣♣ P<0.01 vs NrasG12D/+, 446 
♣♣♣ P<0.001 vs NrasG12D/+), († P<0.05 Npm1cA/+; NrasG12D/+ vs Npm1cA/+; Flt3ITD/+, †† P<0.01 Npm1cA/+; 447 
Nras
G12D/+
 vs Npm1
cA/+
; Flt3
ITD/+
, ††† P<0.001 Npm1
cA/+
; Nras
G12D/+
 vs Npm1
cA/+
; Flt3
ITD/+
). 448 
Figure 2. Impact of Npm1
cA/+
 on the transcriptome of Nras
G12D/+ 
and Flt3
ITD/+ 
mutant hematopoietic 449 
progenitors.  450 
(A) Overlap of differentially expressed mRNAs reveals that Npm1
cA/+
 has a dramatic impact on Lin-451 
progenitor GEPs when combined with Flt3
ITD/+
, but only a modest impact when combined with 452 
Nras
G12D/+
. Nonetheless, the characteristic hallmarks of Npm1
cA/+
 are retained in both double mutant 453 
progenitors, namely overexpression of Hoxa genes and of the homeobox genes Hopx and Nkx2-3 454 
(also seen in single Npm1
cA/+ 
progenitors). Gene Set Enrichment Analysis reveals enrichment of 455 
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differentially expressed genes from these models in human AMLs harboring mutant NPM1 or MLL 456 
gene fusions (B) Comparison of human NPM1-mutant (NPM1
c
)
 
versus NPM1-wildtype (NPM1
WT
) 457 
normal karyotype AML (NK-AML) also shows marked overexpression of HOXA and HOXB genes, as 458 
well as of NKX2.3 raising the possibility that the latter may mediate some of the effect of NPM1
c
. (C) 459 
Effects of Nkx2-3 and Hoxa9 over-expression on mouse hematopoietic progenitors. (i) Lin
-
 bone 460 
marrow progenitors from wildtype and Flt3
ITD/+ 
mice were transduced with MSCV-Nkx2.3-CFP and/or 461 
MSCV-Hoxa9-GFP constructs, maintained in liquid culture for 7 days, FACS sorted for CFP and GFP 462 
single and for double transfected cells and plated in semi-solid media. (ii) Colony assays of 2,500 463 
transduced cells show that both  MSCV-Hoxa9 and MSCV-Nkx2-3 conferred an increase in self-464 
renewal of both wildtype and Flt3
ITD/+ 
cells. However, double MSCV-Hoxa9/MSCV-Nkx2-3 transfected 465 
cells showed no further changes in self-renewal when compared to MSCV-Hoxa9 alone. Mean ± SEM 466 
(n=3); *p<0.05; **p<0.01; ***p<0.001; students t-test). (D) Sorting strategy for 467 
LSK/CD34
+
/Flt3
+
/CD48
+
 progenitor cells and overlap of differentially expressed genes (Illumina 468 
MouseWG-6 v2 Expression BeadChip) for (i) Nras
G12D/+
 vs Npm1
cA/+
;Nras
G12D/+
 and (ii) Flt3
ITD/+ 
vs
 
469 
Npm1
cA/+
;Flt3
ITD/+
 MPPs datasets. (E) Heat map of normalised Hox gene expression in purified (i) MPP 470 
and (ii) Lin
-
 populations reveal that Npm1
cA/+
 mutants (single or double) have similar patterns of Hox 471 
gene expression to wildtype (normalised average expression values are used to generate heat map 472 
values). (F) Differentially expressed genes in Npm1
cA/+
;Flt3
ITD/+
 MPPs vs wildtype controls .  473 
Figure 3. Npm1
cA
 and Nras
G12D
 co-operate to drive high penetrance AML.  474 
(A) Kaplan Meier survival curves of wildtype (n=23), Npm1
cA/+ 
(n=34), Nras
G12D/+ 
(n=40), Flt3
ITD/+ 
475 
(n=39), Npm1
cA/+
;Nras
G12D/+ 
(n=46) and Npm1
cA/+
;Flt3
ITD+/
 (n=40). Double mutant (Npm1
cA/+
;Nras
G12D/+
 476 
and Npm1
cA/+
;Flt3
ITD/+
) mice had a significantly shortened survival when compared to single mutants, 477 
whilst Npm1
cA/+
;Flt3
ITD
 had significantly shorter survival than Npm1
cA/+
;Nras
G12D/+
 mice. (B) Results of 478 
independent histopathological analysis of aged moribund mice.  Incidence of AML in compound 479 
Npm1
cA/+
;Nras
G12D/+
 and Npm1
cA/+
;Flt3
ITD/+
 mice is increased compared to Npm1
cA/+ 
, Nras
G12D/+ 
and 480 
Flt3
ITD/+ 
mice. Examples of complete effacement of splenic tissue and infiltration of myeloid blast 481 
cells in liver tissue from Npm1
cA/+
; Nras
G12D/+ 
and Npm1
cA/+
; Flt3
ITD+/
 AMLs are presented. Reduced 482 
MPO staining in diseased tissues is observed in samples categorized as AML without maturation 483 
(AML-) compared to those categorized as AML with maturation (AML+).  H&E, Haematoxylin and 484 
eosin; MPO, myeloperoxidase. 485 
Figure 4. Leukemic progression in double mutant mice involves increased Nras
G12D
 or Flt3
ITD 
allele 486 
dosage  487 
(A) Increase in Flt3
ITD
 allele burden in AMLs from Npm1
cA
; Flt3
ITD
 mice through loss of heterozygosity 488 
for the locus. (i) Flt3
ITD
 amplicon sequencing (MiSeq) of leukemic bone marrow or spleen DNA (FN2-489 
FN7). Tail DNA amplified from 2-week-old Flt3
+/+
, Flt3
ITD/+
, Flt3
ITD/ITD
 mice was used as control. (ii)  490 
Normalised Log2 ratio plots show copy neutrality of chr5 and the Flt3 locus in 7/7 Npm1
cA
; Flt3
ITD 
491 
murine AMLs (FN-AMLs) tested. (B) (i) Summary of aCGH showing copy number gain at the Nras 492 
locus in AMLs RN6-10. (ii) Allele fractions for Nras
wt
 vs Nras
G12D
 show that copy number gains in RN6-493 
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10 involved Nras
G12D
, and that an additional 3 cases (RN3-5) show copy-neutral loss-of-494 
heterozygosity. In addition, two more RN AMLs show gains in mutant NRAS when measuring Nras
wt
 495 
vs Nras
G12D
 allele fractions (aCGH was not performed on these). Results of two Npm1
cA/+ 
samples are 496 
also shown for comparison purposes (N6, N7). (C) Increased gene dosage of Nras
G12D
 correlates with 497 
increased levels of phosphorylated RAS effectors pERK1/2. FN2,3,4,6,7= Npm1
cA
;Flt3
ITD
 AML, RN1-498 
14= Npm1
cA/+
;Nras
G12D/+
 AML. 499 
Figure 5.  Somatic mutations in Npm1
cA/+
, Npm1
cA/+
; Nras
G12D/+
 and Npm1
cA
; Flt3
ITD
AMLs.  (A) Exome 500 
sequencing identifies an increased number of somatic nucleotide variants (SNVs) and small indels in 501 
Npm1
cA/+
, compared to Npm1
cA/+
; Nras
G12D/+ 
(RN-AML) and Npm1
cA
; Flt3
ITD
 (FN-AML) AML samples. 502 
Npm1
cA/+
 6.8±0.9, Npm1
cA/+
; Nras
G12D/+
 3.3±0.5 and Npm1
cA/+
; Flt3
ITD/+
2.6±0.7 (mean±SEM) (** p<0.01 503 
vs Npm1
cA/+
 one way ANOVA, Bonferroni adjusted). Total AMLs sequenced; Npm1
cA/+ 
(n=12), 504 
Npm1
cA/+
; Nras
G12D/+
 (n=14) and Npm1
cA
; Flt3
ITD
 (n=7).
 
(B) Summary of SNVs/Indels detected in AMLs 505 
from each genotype as indicated. Those in blue are genes mutated in the TCGA AML dataset. Those 506 
in red are exact or synonymous mutations detected in the TCGA AML dataset. (C) Co-occurrence of 507 
SNVs and CNVs. Depicted are SNVs and focal copy number variations (CNVs) which have been 508 
formally detected in the TCGA AML
19
 dataset or detected as common insertion sites (CIS) in our 509 
previously published Npm1
cA/+ 
Sleeping Beauty Transposon screen 
18 
. Mutant allele copy gains, 510 
chromosome gains and losses depicted. For copy number variation, colour coded boxes are based on 511 
log2 ratios (aCGH) and are not representative of CNV size. For a complete overview of all CNV and 512 
SNV co-occurrence see Supplemental Figure S6. 513 
Figure 6. MLL, Hox genes and their partners are required for the survival of Npm1
cA
-driven AML 514 
cells. (A) Schematic depicting the derivation and liquid culture of Rosa26-EF1-Cas9 expressing AML 515 
cell lines. CRISPR-EF1-Cas9 based assessment of individual genes aberrantly expressed in 516 
Npm1
cA/+
;Nras
G12D/+
 and Npm1
cA
;Flt3
ITD
 mice. CAS9 activity of these mouse AML cell lines was 517 
validated as described previously (Supplementary Figure S7A).
11
 Individual Rosa26-EF1-Cas9 518 
expressing cell lines were derived from two mice of each genotype. In vitro competitive assays were 519 
performed over a 23 day period using AML cell lines transduced with lentivirus expressing gRNAs for 520 
the indicated gene, and the BFP-positive fraction compared with the non-transduced population. 521 
Results were normalized to day 3 for each gRNA. Results from AML cell lines transduced with guide 522 
RNAs targeting Hoxa-related (B) and non-Hoxa related (C) genes. gRNA sequences were selected 523 
from a previously published library
11
 and are detailed in Supplementary Table S15. Guides against 524 
the pan essential Npm1 gene are used as a control. 525 
 526 
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